

# Benjamin A Derman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4344527/publications.pdf>

Version: 2024-02-01

34  
papers

609  
citations

840776

11  
h-index

610901

24  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1111  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of advanced squamous cell carcinoma of the lung: a review. <i>Translational Lung Cancer Research</i> , 2015, 4, 524-32.	2.8	74
2	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	7.2	69
3	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. <i>Blood Advances</i> , 2019, 3, 3488-3498.	5.2	62
4	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	1.4	56
5	Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. <i>BMC Cancer</i> , 2017, 17, 141.	2.6	53
6	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. <i>Blood Advances</i> , 2020, 4, 2810-2820.	5.2	47
7	Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2021, 11, 19.	6.2	40
8	Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. <i>Blood Cancer Journal</i> , 2020, 10, 80.	6.2	35
9	Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 614-622.	1.3	29
10	Risk Factors, Diagnosis, Management, and Outcome of Splanchnic Vein Thrombosis: A Retrospective Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 503-513.	2.7	23
11	Recommendations for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1058.	7.4	13
12	Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. <i>Blood Advances</i> , 2020, 4, 4924-4928.	5.2	12
13	Sex differences in outcomes in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 192, e66-e69.	2.5	12
14	Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. , 2020, 8, e000286.		11
15	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
16	Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program. <i>JCO Oncology Practice</i> , 2021, 17, e445-e453.	2.9	10
17	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. <i>Journal of Geriatric Oncology</i> , 2021, 12, 585-591.	1.0	10
18	Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101102.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Knowing the unknowns in high risk multiple myeloma. <i>Blood Reviews</i> , 2022, 51, 100887.	5.7	6
20	Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma. <i>International Journal of Nephrology</i> , 2018, 2018, 1-6.	1.3	5
21	Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. <i>Blood</i> , 2019, 134, 4606-4606.	1.4	5
22	A small field for fertile science: the low visibility of reproductive science in high impact journals. <i>Journal of Assisted Reproduction and Genetics</i> , 2014, 31, 511-520.	2.5	4
23	Efficacy and tolerability of a modified pediatricâ€inspired intensive regimen for acute lymphoblastic leukemia in older adults. <i>EJHaem</i> , 2021, 2, 413-420.	1.0	4
24	Bendamustine-induced nephrogenic diabetes insipidus. <i>Clinical Nephrology</i> , 2017, 87, 47-50.	0.7	4
25	Breast cancer in postmenopausal women after non-melanomatous skin cancer: the Womenâ€™s Health Initiative observational study. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 821-831.	2.5	3
26	ATTR Cardiomyopathy Meets Multipleâ€Myeloma. <i>JACC: CardioOncology</i> , 2021, 3, 598-601.	4.0	2
27	Clinician attitudes and practices toward measurable residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 190, 470-472.	2.5	1
28	Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	1
29	Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1000-e1008.	0.4	1
30	Nitric Oxide, Coagulation and Cancer. , 2015, , 281-295.		0
31	Risk Factors, Diagnosis, Management, and Outcomes For Splanchnic Vein Thrombosis: A Retrospective Analysis. <i>Blood</i> , 2013, 122, 2372-2372.	1.4	0
32	Disparities in Renal Recovery Between African Americans Vs. Non African Americans Following Initial Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Chart Review. <i>Blood</i> , 2016, 128, 5610-5610.	1.4	0
33	Real-World Validity of the Revised International Staging System in Multiple Myeloma By Race. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
34	Moving Toward a Cure in Multiple Myeloma: Eradication of Measurable Residual Disease. <i>Advances in Oncology</i> , 2022, 2, 159-169.	0.2	0